Profile
Andrew D.
Ashe formerly worked at Nutter McClennen & Fish LLP, as Member-Business Law Practices, Prince Lobel Tye LLP, as Member-Business Law Practices, Verve Therapeutics, Inc., as President, COO & General Counsel from 2021 to 2025, Dyax Corp., as General Counsel & EVP-Operations & Administration from 2013 to 2016, and Beacon Therapeutics (USA), Inc., as General Counsel from 2017 to 2018.
Mr. Ashe received his graduate degree from George Washington University Law School and undergraduate degree from The Isenberg School of Management.
Former positions of Andrew Ashe
| Companies | Position | End |
|---|---|---|
| VERE THER | Director of Finance/CFO | 2021-11-28 |
| APPLIED GENETIC TECHNOLOGIES CORPORATION | General Counsel | 2018-07-31 |
| DYAX CORP. | Chief Administrative Officer | 2015-12-31 |
Nutter McClennen & Fish LLP
Nutter McClennen & Fish LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Prince Lobel Tye LLP
Prince Lobel Tye LLP Miscellaneous Commercial ServicesCommercial Services Prince Lobel Tye LLP is a full-service law firm with over 100 attorneys offering legal services across a wide range of practice areas, including business and appellate litigation, intellectual property, corporate law, employment law, family law, real estate, environmental law, trusts and estates, media, telecommunications, energy, internal investigations, and data privacy. The private company is based in Boston, MA. The firm also operates Prince Lobel Strategic Advisors, which provides nationwide strategic advisory services to start-ups and emerging growth companies in areas such as cannabis licensing and compliance, business documentation, financial modeling, mergers and acquisitions, exit strategies, and IPOs, without offering legal advice or establishing attorney-client relationships. | Corporate Officer/Principal | - |
Training of Andrew Ashe
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
Dyax Corp.
Dyax Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in development and commercialization of novel biotherapeutics | Health Technology |
Nutter McClennen & Fish LLP
Nutter McClennen & Fish LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Beacon Therapeutics (USA), Inc.
Beacon Therapeutics (USA), Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical research and development company that provides gene therapy development & clinical research services | Health Technology |
Prince Lobel Tye LLP
Prince Lobel Tye LLP Miscellaneous Commercial ServicesCommercial Services Prince Lobel Tye LLP is a full-service law firm with over 100 attorneys offering legal services across a wide range of practice areas, including business and appellate litigation, intellectual property, corporate law, employment law, family law, real estate, environmental law, trusts and estates, media, telecommunications, energy, internal investigations, and data privacy. The private company is based in Boston, MA. The firm also operates Prince Lobel Strategic Advisors, which provides nationwide strategic advisory services to start-ups and emerging growth companies in areas such as cannabis licensing and compliance, business documentation, financial modeling, mergers and acquisitions, exit strategies, and IPOs, without offering legal advice or establishing attorney-client relationships. | Commercial Services |
The Isenberg School of Management
The Isenberg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
George Washington University Law School
George Washington University Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Verve Therapeutics, Inc.
Verve Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines to treat patients with cardiovascular disease | Health Technology |
- Stock Market
- Insiders
- Andrew Ashe
















